NervGen Pharma Q2 EPS Estimate Decreased by HC Wainwright

NervGen Pharma (NASDAQ:NGEN) – Equities researchers at HC Wainwright reduced their Q2 2026 earnings per share (EPS) estimates for NervGen Pharma in a note issued to investors on Tuesday, July 14th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($0.11) per share for the quarter, down from their previous estimate of ($0.09). HC Wainwright has a “Strong-Buy” rating on the stock. HC Wainwright also issued estimates for NervGen Pharma’s Q3 2026 earnings at ($0.11) EPS, Q4 2026 earnings at ($0.12) EPS, Q1 2027 earnings at ($0.13) EPS, Q2 2027 earnings at ($0.14) EPS, Q3 2027 earnings at ($0.15) EPS, Q4 2027 earnings at ($0.14) EPS and FY2027 earnings at ($0.56) EPS.

NervGen Pharma (NASDAQ:NGEN) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.02).

A number of other analysts have also commented on the stock. Stifel Nicolaus upgraded shares of NervGen Pharma to a “strong-buy” rating in a research note on Thursday, April 23rd. Leerink Partners assumed coverage on shares of NervGen Pharma in a report on Monday, July 13th. They set an “outperform” rating and a $10.00 price objective for the company. TD Cowen started coverage on shares of NervGen Pharma in a report on Thursday, June 11th. They set a “buy” rating for the company. Weiss Ratings assumed coverage on shares of NervGen Pharma in a research report on Friday, April 24th. They set a “sell (d-)” rating for the company. Finally, Wall Street Zen lowered shares of NervGen Pharma from a “hold” rating to a “sell” rating in a report on Sunday, July 12th. Two investment analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $14.00.

NervGen Pharma Stock Performance

Shares of NGEN opened at $1.67 on Thursday. NervGen Pharma has a 12-month low of $1.59 and a 12-month high of $6.30. The stock has a fifty day moving average price of $2.27. The company has a market cap of $134.65 million and a PE ratio of -18.56.

NervGen Pharma Company Profile

NervGen Pharma Corp. is a clinical-stage biotechnology company focused on developing therapies to promote nerve repair and restore neurological function following injury or disease. The company advances regenerative approaches intended to address damage in the central and peripheral nervous systems, pursuing programs that aim to translate preclinical repair concepts into human treatments.

The company’s lead investigational candidate is NVG-291, which is being evaluated in clinical studies for indications that include spinal cord injury, neuropathic conditions and neurodegenerative disease settings.